Therapy Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Therapy Name Neladalkib
Synonyms
Therapy Description

Nelkarmi (neladalkib) is a brain-penetrant ALK inhibitor active against ALK fusions and mutations, potentially leading to reduced cell growth and tumor regression (PMID: 39269178). Nelkarmi (neladalkib) is FDA-approved for use in patients with ALK-positive non-small cell lung cancer who have received prior ALK inhibitors (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Neladalkib Nelkarmi NVL655|NUV-655|NUV655|NVL-655 ALK Inhibitor 34 Nelkarmi (neladalkib) is a brain-penetrant ALK inhibitor active against ALK fusions and mutations, potentially leading to reduced cell growth and tumor regression (PMID: 39269178). Nelkarmi (neladalkib) is FDA-approved for use in patients with ALK-positive non-small cell lung cancer who have received prior ALK inhibitors (FDA.gov).

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
EML4 - ALK ALK F1174L ALK G1202R Advanced Solid Tumor sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK, ALK G1202R, and ALK F1174L in culture (PMID: 39269178). 39269178
EML4 - ALK ALK L1196M ALK D1203N Advanced Solid Tumor resistant Neladalkib Preclinical - Cell culture Actionable In a preclinical study, cells expressing ALK D1203N and L1196M in the context of EML4-ALK were resistant to Nelkarmi (neladalkib) treatment in culture (PMID: 42129432). 42129432
EML4 - ALK ALK L1198F ALK G1202R Advanced Solid Tumor sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK, ALK G1202R, and ALK L1198F in culture (PMID: 39269178). 39269178
EML4 - ALK ALK G1202del Advanced Solid Tumor sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK and ALK G1202del in culture (PMID: 39269178). 39269178
ALK del exon2-17 sarcoma sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of a soft tissue sarcoma cell line harboring a deletion of ALK exons 2-17 in culture (PMID: 39269178). 39269178
EML4 - ALK ALK T1151M ALK G1202R lung non-small cell carcinoma sensitive Neladalkib Preclinical - Pdx & cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited Alk signaling and viability of a patient-derived non-small cell lung cancer cell line expressing EML4-ALK, ALK G1202R, and ALK T1151M in culture and induced tumor regression in a patient-derived xenograft (PDX) model (PMID: 39269178). 39269178
EML4 - ALK ALK I1171N Advanced Solid Tumor predicted - sensitive Neladalkib Preclinical Actionable In a preclinical study, Nelkarmi (neladalkib) moderately inhibited viability cells expressing EML4-ALK and ALK I1171N in culture and inhibited tumor growth in a transplant model (PMID: 39269178). 39269178
EML4 - ALK ALK T1151dup Advanced Solid Tumor sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK and ALK T1151dup (reported as T1151insT) in culture (PMID: 39269178). 39269178
EML4 - ALK ALK S1206F Advanced Solid Tumor sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK and ALK S1206F in culture (PMID: 39269178). 39269178
ALK fusion lung non-small cell carcinoma sensitive Neladalkib FDA approved Actionable In a Phase I/II trial (ALKOVE-1) that supported FDA approval, Nelkarmi (neladalkib) treatment resulted in an objective response rate of 31% (79/253) in patients with ALK-positive non-small cell lung cancer who have received prior ALK inhibitor treatments, with duration of response over 12 mo in 64% and over 18 mo in 53% of patients (J Clin Oncol (2026) 44 (suppl_16): 8503; NCT05384626). detail...
EML4 - ALK ALK G1202R ALK G1269A lung adenocarcinoma predicted - sensitive Neladalkib Case Reports/Case Series Actionable In a Phase I trial (ALKOVE-1), Nelkarmi (neladalkib) treatment resulted in a partial response with treatment ongoing for at least 5 months in a patient with metastatic lung adenocarcinoma harboring EML4-ALK, ALK G1202R, and ALK G1269A (PMID: 39269178; NCT05384626). 39269178
EML4 - ALK ALK S1206Y Advanced Solid Tumor sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK and ALK S1206Y in culture (PMID: 39269178). 39269178
EML4 - ALK ALK I1171T Advanced Solid Tumor predicted - sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) moderately inhibited viability of cells expressing EML4-ALK and ALK I1171T in culture (PMID: 39269178). 39269178
EML4 - ALK ALK L1196M ALK G1202R lung non-small cell carcinoma sensitive Neladalkib Preclinical - Pdx & cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited Alk signaling and viability of a patient-derived non-small cell lung cancer cell line harboring EML4-ALK, ALK G1202R, and ALK L1196M in culture and induced tumor regression in a patient-derived xenograft (PDX) model and a cell line xenograft model (PMID: 39269178). 39269178
EML4 - ALK ALK T1151M Advanced Solid Tumor sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK and ALK T1151M in culture (PMID: 39269178). 39269178
EML4 - ALK ALK L1196M Advanced Solid Tumor predicted - sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) moderately inhibited viability of cells expressing EML4-ALK and ALK L1196M in culture (PMID: 39269178). 39269178
EML4 - ALK Advanced Solid Tumor predicted - sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK in culture (PMID: 39269178). 39269178
EML4 - ALK ALK G1202R Advanced Solid Tumor predicted - sensitive Neladalkib Preclinical Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK and ALK G1202R in culture and inhibited tumor growth in a transplant model (PMID: 39269178). 39269178
EML4 - ALK ALK I1171S Advanced Solid Tumor predicted - sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) moderately inhibited viability of cells expressing EML4-ALK and ALK I1171S in culture (PMID: 39269178). 39269178
EML4 - ALK lung adenocarcinoma sensitive Neladalkib Case Reports/Case Series Actionable In a Phase I trial (ALKOVE-1), Nelkarmi (neladalkib) treatment resulted in a complete response in the central nervous system metastases and an overall partial response with treatment ongoing for at least 9 months in a patient with metastatic lung adenocarcinoma harboring EML4-ALK (PMID: 39269178; NCT05384626). 39269178
EML4 - ALK ALK G1202R lung non-small cell carcinoma predicted - sensitive Neladalkib Preclinical - Pdx & cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited Alk signaling and growth in patient-derived non-small cell lung cancer cell lines harboring EML4-ALK and ALK G1202R in culture and decreased brain tumor growth and improved survival in a patient-derived intracranial xenograft model (PMID: 39269178). 39269178
EML4 - ALK ALK F1174C ALK G1202R lung adenocarcinoma sensitive Neladalkib Case Reports/Case Series Actionable In a Phase I trial (ALKOVE-1), Nelkarmi (neladalkib) treatment resulted in a partial response with treatment ongoing for at least 9 months in a patient with metastatic lung adenocarcinoma harboring EML4-ALK with ALK G1202R and F1174C in cis (PMID: 39269178; NCT05384626). 39269178
EML4 - ALK ALK I1171N ALK D1203N Advanced Solid Tumor resistant Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) did not inhibit viability of cells expressing EML4-ALK, ALK I1171N, and ALK D1203N (PMID: 39269178). 39269178
EML4 - ALK ALK G1202R ALK G1269A Advanced Solid Tumor predicted - sensitive Neladalkib Preclinical Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK, ALK G1202R, and ALK G1269A in culture and induced tumor regression in a transplant model (PMID: 39269178). 39269178
EML4 - ALK lung non-small cell carcinoma sensitive Neladalkib Preclinical - Cell line xenograft Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited growth of a patient-derived non-small cell lung cancer cell line harboring EML4-ALK in culture and inhibited growth of a cell line xenograft model (PMID: 39269178). 39269178
EML4 - ALK ALK C1156Y Advanced Solid Tumor sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK and ALK C1156Y in culture (PMID: 39269178). 39269178
EML4 - ALK ALK L1196Q Advanced Solid Tumor sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK and ALK L1196Q in culture (PMID: 39269178). 39269178
EML4 - ALK ALK L1198F Advanced Solid Tumor sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK and ALK L1198F in culture (PMID: 39269178). 39269178
EML4 - ALK ALK D1203N Advanced Solid Tumor predicted - sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) moderately inhibited viability of cells expressing EML4-ALK and ALK D1203N in culture (PMID: 39269178). 39269178
ALK act mut neuroblastoma predicted - sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited proliferation of neuroblastoma cell lines harboring activating mutations in ALK in culture (Cancer Res (2022) 82 (12_Supplement): 3337). detail...
ALK rearrange lung non-small cell carcinoma sensitive Neladalkib FDA approved Actionable In a Phase I/II trial (ALKOVE-1) that supported FDA approval, Nelkarmi (neladalkib) treatment resulted in an objective response rate of 31% (79/253) in patients with ALK-positive non-small cell lung cancer who have received prior ALK inhibitor treatments, with duration of response over 12 mo in 64% and over 18 mo in 53% of patients (J Clin Oncol (2026) 44 (suppl_16): 8503; NCT05384626). detail...
ALK F1174L neuroblastoma sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of neuroblastoma cell lines harboring ALK F1174L in culture (PMID: 39269178). 39269178
EML4 - ALK ALK G1269A Advanced Solid Tumor predicted - sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) moderately inhibited viability of cells expressing EML4-ALK and ALK G1269A in culture (PMID: 39269178). 39269178
ALK fusion ALK G1202R lung non-small cell carcinoma predicted - sensitive Neladalkib Phase Ib/II Actionable In a Phase I/II trial (ALKOVE-1), Nelkarmi (neladalkib) treatment resulted in an objective response rate of 68% (32/47) in patients with ALK-positive non-small cell lung cancer harboring ALK G1202R who have received prior ALK inhibitor treatments, with duration of response over 12 mo in 80% of patients (J Clin Oncol (2026) 44 (suppl_16): 8503; NCT05384626). detail...
EML4 - ALK ALK L1196M lung non-small cell carcinoma sensitive Neladalkib Preclinical - Patient cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited Alk signaling and growth in a patient-derived non-small cell lung cancer cell line harboring EML4-ALK and ALK L1196M in culture (PMID: 39269178). 39269178
EML4 - ALK ALK L1196M ALK G1202R Advanced Solid Tumor sensitive Neladalkib Preclinical Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK, ALK G1202R, and ALK L1196M in culture and induced tumor regression in a transplant model and decreased brain tumor volume and increased survival in an intracranial transplant model (PMID: 39269178). 39269178
EML4 - ALK ALK E1210K Advanced Solid Tumor sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK and ALK E1210K in culture (PMID: 39269178). 39269178
ALK del exon2-3 ALK amp neuroblastoma sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of an ALK-amplified neuroblastoma cell line harboring a deletion of ALK exons 2-3 in culture (PMID: 39269178). 39269178
EML4 - ALK ALK K1150dup Advanced Solid Tumor resistant Neladalkib Preclinical - Cell culture Actionable In a preclinical study, cells expressing ALK K1150dup in the context of EML4-ALK were resistant to Nelkarmi (neladalkib) treatment in culture (PMID: 42129432). 42129432
ALK amp neuroblastoma predicted - sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited proliferation of neuroblastoma cell lines with ALK amplification in culture (Cancer Res (2022) 82 (12_Supplement): 3337). detail...
EML4 - ALK ALK V1180L Advanced Solid Tumor sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK and ALK V1180L in culture (PMID: 39269178). 39269178
EML4 - ALK ALK I1171N ALK L1198F Advanced Solid Tumor predicted - sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) moderately inhibited viability of cells expressing EML4-ALK, ALK I1171N, and ALK L1198F in culture (PMID: 39269178). 39269178
EML4 - ALK ALK T1151M ALK G1202R Advanced Solid Tumor sensitive Neladalkib Preclinical - Cell culture Actionable In a preclinical study, Nelkarmi (neladalkib) inhibited viability of cells expressing EML4-ALK, ALK G1202R, and ALK T1151M in culture (PMID: 39269178). 39269178

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05384626 Phase Ib/II Itraconazole + Neladalkib Midazolam + Neladalkib + Repaglinide Neladalkib A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) Recruiting USA | NLD | ITA | GBR | FRA | ESP | DEU | CHE | CAN | BEL | AUS 4
NCT06765109 Phase III Alectinib Neladalkib Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC (ALKAZAR) Recruiting USA | POL | NLD | ITA | HUN | GRC | GBR | FRA | ESP | DNK | DEU | CZE | CHE | CAN | BRA | BEL | AUT | AUS | ARG 10
NCT06834074 Expanded access Neladalkib Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors (NVL-655-EAP) Available USA | NLD | ITA | GBR | FRA | ESP | CHE | CAN | AUS 3


Additional content available in Icon for CKB-BoostCKB BOOST